Improved hemodynamics and cardiopulmonary function in patients with inoperable chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty

Table 1 Baseline characteristics of patients with inoperable CTEPH

Variables	Values
Patients, n	25
Male/Female, n	13/12
Age, years	58.2 ± 9.8
BMI, kg/m²	23.6 ± 3.4
WHO-FC I/II/III/IV^a, n	1/11/13/0
DVT, n (%)	8 (32%)
Duration from onset to admission^a, years	3.0 (1.1–5.5)
SaO₂^a, %	91.3 ± 2.3
SvO₂^a, %	68.9 ± 5.3
mRAP^a, mmHg	7.4 ± 3.3
mPAP^a, mmHg	49.4 ± 13.4
PVR^a, dyne·s·cm⁻⁵	952.01 ± 375.38
CI^a, l/min/m²	3.18 ± 0.74
PAWP^a, mmHg	10.2 ± 3.0
PH targeted medication^a, n (%)	19 (76%)
Monotherapy, n (%)	14 (56%)
ERAs	2 (8%)
PDE-5is	8 (32%)
sGCs	4 (16%)
Combined therapy, n (%)	5 (20%)
ERAs+PDE-5is, n (%)	5 (20%)
6MWD^a, m	331.8 ± 111.3
Number of BPA sessions, n	40
Number of treated segments per session, n	3.4 ± 1.6
Number of treated vessels per session, n	4.6 ± 1.9
Number of balloons per session, n	1.4 ± 0.5

BMI body mass index, WHO-FC WHO functional class, DVT deep vein thrombosis, SaO₂ arterial oxygen saturation, SvO₂ mixed venous oxygen saturation, mRAP mean right atrial pressure, mPAP mean pulmonary artery pressure, PVR pulmonary vascular resistance, CI cardiac index, PAWP pulmonary arterial wedge pressure, PH pulmonary hypertension, ERAs endothelin receptor antagonists, PDE-5is phosphodiesterase-5 inhibitors, sGCs soluble guanylate cyclase stimulators, 6MWD 6-min walk distance, BPA balloon pulmonary angioplasty
^aData at the first admission

ISSN: 1465-993X